Diaceutics (LON:DXRX) Price Target Raised to GBX 215

Diaceutics (LON:DXRX) had its target price upped by investment analysts at Shore Capital from GBX 180 to GBX 215 in a report issued on Thursday,London Stock Exchange reports. The brokerage presently has a “buy” rating on the stock. Shore Capital’s target price suggests a potential upside of 37.82% from the stock’s previous close.

Diaceutics Trading Up 10.2%

Shares of Diaceutics stock traded up GBX 14.50 during trading on Thursday, hitting GBX 156. The stock had a trading volume of 248,932 shares, compared to its average volume of 286,775. Diaceutics has a 1 year low of GBX 106 and a 1 year high of GBX 168. The stock has a 50 day simple moving average of GBX 144.13 and a 200 day simple moving average of GBX 143.73. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. The company has a market capitalization of £132.02 million, a PE ratio of -86.67 and a beta of 0.58.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.